版本:
中国

BRIEF-Pieris pharma presents IND-enabling data

April 4 Pieris Pharmaceuticals Inc:

* Pieris Pharmaceuticals presents IND-enabling data for bispecific immuno-oncology drug candidate, PRS-343, in poster session at the 2017 meeting of the American Association For Cancer Research (AACR)

* Pieris Pharma-data presented shows PRS-343 elicited robust t cell activation when engaging her2 on cell lines derived from tumors resistant to trastuzumab therapy

* Pieris Pharmaceuticals -PRS-343 was well tolerated and led to no significant findings in ind-enabling preclinical safety and non-human primate toxicology studies

* Pieris Pharma-4-1bb-mediated t cell activation by PRS-343 resulted in expression of broad spectrum of inflammatory cytokines associated with anti-tumor immune responses Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐